LYELLyell Immunopharma, Inc.Signing up patients
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
Relapsed Non-Hodgkin Lymphoma · Refractory Non-Hodgkin Lymphoma · Non-Hodgkin Lymphoma · Large B-cell Lymphoma
4Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +4.1
4 insiders sold shares within a month
Since Aug 21, 2026 · was worth 10, fading over time
Worry score4
Score over time
- Stage
- Phase 1/2
- Patients
- 270 (planned)
- Started
- May 9, 2023
- Main results expected
- Dec 31, 2028
- Fully finished
- Jun 30, 2031
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Phase 1: Evaluate the safety and tolerability of a single dose of ronde-cel administered as a single agent
Measured over: Baseline to Month 24
Phase 2: Estimate the efficacy of ronde-cel, as measured by overall response rate (ORR)
Measured over: Baseline to Month 24
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 10, now 4.1, since 2026-08-21, fades (half-life)
Raw record changes
- none yet
Trial ID NCT05826535 · record last updated 2026-08-25 · checked 2026-11-09 15:47 UTC